Detalhe da pesquisa
1.
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
Breast Cancer Res Treat
; 115(1): 115-21, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18496750
2.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
N Engl J Med
; 353(16): 1673-84, 2005 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16236738
3.
Concordance between central and local laboratory HER2 testing from a community-based clinical study.
Clin Breast Cancer
; 7(2): 153-7, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16800975
4.
Trastuzumab and cardiac dysfunction: update on preclinical studies.
Semin Oncol
; 30(5 Suppl 16): 49-53, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14613026
5.
Lavage and nipple aspiration of breast ductal fluids: a source of biomarkers for environmental mutagenesis.
Environ Mol Mutagen
; 39(2-3): 127-33, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-11921180
6.
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
J Clin Oncol
; 31(17): 2128-35, 2013 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23650416
7.
Development of the breast cancer education and risk assessment program.
Oncol Nurs Forum
; 30(5): 803-8, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12949593